Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice

European Journal of Clinical Investigation

Volumn 26, Issue 6, 1996, Pages 427-435

  Malle, E ^a   De Beer, F C ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acute phase response; Allograft rejection; Amyloidosis; Apolipoproteins; Cytokine mediated induction; Plasma lipoprotein

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN;

ACUTE PHASE RESPONSE; AMYLOIDOSIS; ATHEROGENESIS; BLOOD VESSEL INJURY; CLINICAL PRACTICE; DIAGNOSTIC VALUE; GRAFT REJECTION; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029886548     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.159291.x     Document Type: Review

References (76)

1. Kushner I. The acute phase response: An overview. Methods Enzymol 1988;163:373-83.
2. Fey GH, Hocke GM, Wilson DR et al. Cytokines and acute phase response of the liver. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, eds. The Liver: Biology and Pathobiology, 3rd edn. New York: Raven Press Ltd., 1994:113-43.
3. Edbrooke MR, Burt DW, Cheshire JK, Woo P. Identification of cis-acting sequences responsible for phorbol ester induction of human serum amyloid A gene expression via a nuclear factor κ-B-like transcription factor. Mol Cell Biol 1989;9:1908-16.
4. Edbrooke MR, Foldi J, Cheshire JK, Li F, Faulkes DJ, Woo P. Constitutive and NF-κB-like proteins in the regulation of the serum amyloid A gene by interleukin J. Cytokine 1993;3: 380-8.
5. Betts JC, Cheshire JK, Akira S, Kashimoto T, Woo P. The role of NF-κB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993;268:25624-31.
6. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993;102:131-46.
7. Steel DM, Sellar GC, Uhlar CM, Simon S, DeBeer FC. Whitehead AS. A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with, an acute-phase serum amyloid A protein gene (SAA2). Genomics 1993;16:447-54.
8. Whitehead AS, de Beer MC, Steel DM et al. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 1992;267:3862-7.
9. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 1991;10:651-61.
10. Strachan AF, Brandt WF, Woo P et al. Human serum amyloid A protein. The assignment of the six major isoforms to three published gene sequences and evidence for two genetic loci. J Biol Chem 1989;264:18368-73.
11. Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 1994;19:228-35.
12. Baussermann LL, Bernier DN, McAdam KPWJ, Herbert PN. Serum amyloid A and high density lipoproteins during the acute phase response. Eur J Clin Invest 1988;18:619-26.
13. Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA 1977;74:4025-8.
14. Malmendier CL, Christophe J, Ameryckx JP. Separation and partial characterization of new apoproteins from human plasma high density lipoproteins. Clin Clin Acta 1979;99:167-76.
15. Eriksen N, Benditt EP. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci USA 1980;77:6860-4.
16. Malmendier CL, Lontie J-F, Delcroix C. In vivo metabolism of alipoprotein S in humans. Comparison with apolipoprotein A-I metabolism. Clin Chim Acta 1987;170:169-80.
17. Malmendier CL, Ameryckx JP. Apoprotein S, a family of human serum lipoprotein polypeptides. Atherosclerosis 1982: 42:161-72.
18. 1. Presumptive identification of calcium and lipid binding sites. Mol Biol Med 1986;3:387-407.
19. 3+ as a specific probe for time-resolved fluorometric assay. J Immunol Methods 1995;182: 131-44.
20. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 1985;26:1389-98.
21. Coetzee GA, Strachan AF, van der Westhuyzen DR et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986; 261:9644-51.
22. Eriksen N, Benditt EP. Trauma, high density lipoproteins, and serum amyloid protein A. Clin Chim Acta 1984;140:139-49.
23. Huschekk A, Skogen B, Husby G. High-density lipoprotein has different binding capacity for different apoproteins. The amyloidogenic apoproteins are easier to displace from high-density lipoproteins. Scand J Immunol 1988;28:653-8.
24. Baussermann LL, Herbert PN. Degradation of serum amyloid A and apolipoproteins by serum proteases. Biochemistry 1984; 23:2241-5.
25. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1992;66:778-85.
26. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995;36:1058-65.
27. p) binds cholesterol and modulates cholesterol flux. J Lipid Res 1995;36:37-46.
28. Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart J-C. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989;1006:173-8.
29. Liao F, Andalibi A, Qiao J-H, Allayee H, Kogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994;94:877-84.
30. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993;91:2572-9.
31. Quai J-H, Castellani LW, Fishbein MC, Lusis AJ. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb 1993;13:932-43.
32. Meek RL, Urieli-Shoval S, Benditt FP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc Natl Acad Sci USA 1994;91:3186-90.
33. 4) as an apolipoprotein. J Lipid Res 1995;36: 526-34.
34. 4): its constitutive presence in serum. Amyloid: Int J Exp Clin Invest 1994;1:14-18.
35. Mozes G, Friedman N, Shainkin-Kestenbaum R. Serum amyloid A: an extremely sensitive marker for intensity of tissue damage in trauma patients and indicator of acute response in various diseases. J Trauma 1989;29:71-4.
36. Saile R, Kabbaj O, Visvikis S et al. Variations in apolipoproteins serum amyloid A, A-I, A-II, and C-III in severely head-injured patients. J Clin Chem Clin Biochem 1990;28: 519-25.
37. McAdam KPWJ, Elin RJ, Sipe JD, Wolff SM. Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest 1978;61: 390-4.
38. Maury CPJ. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci 1985;68:233-8.
39. Marhaug G, Harklau L, Olsen B, Husby G, Husebekk A, Wang H. Serum amyloid A protein in acute myocardial infarction. Acta Med Scand 1986;220:303-6.
40. Wilkins J, Gallimore JR, Tennent GA et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994;40: 1284-90.
41. Raynes JG, McAdam KPWJ. Serum amyloid A isoforms in inflammation. Scand J Immunol 1991;33:657-66.
42. Shainkin-Kestenbaum R, Winikoff Y, Cristal N. Serum amyloid A concentration during the course of acute ischaemic heart disease. J Clin Pathol 1986;39:635-7.
43. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
44. Benson MD, Cohen AS. Serum amyloid A protein in amyloidosis, rheumatic and neoplastic diseases. Arthritis Rheum 1979; 22:36-42.
45. Kumon Y, Suehiro T, Ikeda Y, Yoshida K, Hashimoto K, Ohno F. Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Clin Biochem 1993;26:505-11.
46. De Beer FC, Fagan EA, Hughes GRV, Mallya RK, Lanham JG, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;ii:231-3.
47. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson M. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994;1226:323-9.
48. Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta 1995;1270:81-6.
49. Nakayama T, Sonoda S, Urano T, Yamada T, Okada M. Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases. Clin Chem 1993;39:293-7.
50. Shainkin-Kestenbaum R, Zimlichman S, Winikoff Y, Pras M, Chaimovitz C, Sarov I. Serum amyloid A (SAA) in viral infection: rubella, measles and subacute sclerosing panencephalitis (SSPE). Clin Exp Immunol 1982;50:503-6.
51. Sarov I, Shainkin-Kestenbaum R, Zimlichman S, Winikoff Y, Chaimovitz C, Pras M. Serum amyloid A levels in patients with infections due to cytomegalovirus, varicella-zoster virus, and herpes simplex virus. J Infect Dis 1982;146:443.
52. Miwata H, Yamada T, Okada M, Kudo T, Kimura H, Morishima T. Serum amyloid A protein in acute viral infections. Arch Dis Childhood 1993;68:210-4.
53. Smith JW, Colombo JL, McDonald TL. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients. J Clin Lab Anal 1992;6:219-24.
54. Hijmans W, Sipe JD. Levels of the serum amyloid A protein (SAA) in normal persons of different age groups. Clin Exp Immunol 1979;35:96-100.
55. Rosenthal CJ, Franklin EC. Variation with age and disease of an amyloid A protein-related serum component. J Clin Invest 1975;55:746-53.
56. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zahmcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984;19:193-8.
57. Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. Ann Int Med 1979;91:383-90.
58. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986;39:794-7.
59. Maury CPJ, Teppo AM, Eklund B, Ahonen J. Serum amyloid A protein: a sensitive indicator of renal allograft rejection in humans. Transplantation 1983;36:501-4.
60. Maury CPJ, Teppo AM, Ahonen J, van Willebrand E. Measurements of serum amyloid A protein concentrations as test of renal allograft rejection in patients with initially non-functioning grafts. Br Med J 1984;288:360-1.
61. 2-microglobulin as markers of renal allograft rejection. Clin Nephrol 1984;22:284-92.
62. Hocke G, Ebel H, Bittner K, Müller T, Kaffarnik H, Steinmetz A. A rapid laser immunonephelometric assay for serum amyloid A (SAA) and its application to the diagnosis of the kidney allograft rejection. Klin Wochenschr 1989;67:447-51.
63. Müller T, Sprenger H, Keuchel M, Neumann C, Ebel H, Gemsa D, Lange H. Diagnosis of viral infections under therapy with OKT3 and antithymocyte globulin. Transplant Proc 1992;24: 2636-8.
64. Müller T, Schindler S, Sprenger H et al. Prospective analysis of 10 different parameters of acute renal allograft rejection. Transplant Proc 1992;24:2731-4.
65. Honkanen E, Grönhagen-Riska C, Teppo A-M, Maury CPJ, Meri S. Acute-phase proteins during hemodialysis: correlations with serum interleukin-1β levels and different dialysis membranes. Nephron 1991;57:283-7.
66. Maury CPJ, Höckerstedt K, Teppo AM, Lautenschlager I, Scheinin TM. Changes in serum amyloid A protein and beta-2-microglobulin in association with liver allograft rejection. Transplantation 1984;38:551-3.
67. Lalli E, Meliconi R, Conte R et al. Serum markers of immune activation and liver allograft rejection. Digest Dis Sci 1992;37: 1116-20.
68. Feussner G, Stech C, Dobmeyer J, Schaefer H. Otto G, Ziegler R. Serum amyloid A protein (SAA): a marker for liver allograft rejection in humans. Clin Invest 1994;72:1007-11.
69. Uguccioni M, Meliconi R, Lalli E et al. Serum amyloid A protein concentrations in bone marrow transplantation for β thalassaemia. J Clin Pathol 1992;45:348-51.
70. Berliner JA, Navab M, Fogelman AM et al. Athreosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
71. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-53.
72. Van Lenten BJ, Hama SY, deBeer FC et al. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
73. Badolato R, Wang JM, Murphy WJ et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994;180:203-9.
74. Urieli-Shoval S, Meek RL, Hanson RH, Eriksen N, Benditt EP. Human serum amyloid A genes are expressed in monocyte/ macrophage cell lines. Am J Pathol 1994;145:650-60.
75. Rosenson RDS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993;22:933-40.
76. Kluve-Beckerman B, Malle E, Vitt H, Pfeiffer C, Benson M, Steinmetz A. Characterization of an isoelectric focusing variant of SAA1 (ASP-72) in a family of Turkish origin. Biochem Biophys Res Commun 199I;181:1097-102.